Compare AbbVie Inc (ABBV) vs Home Depot Inc (HD) Price & Performance

AbbVie (ABBV) trades at $249.94, up 1.59% with bullish technical signals and strong analyst support. The company demonstrates solid revenue growth to $61.16B in 2025, though net margins have compressed to 6.9%. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.65 surpassing estimates. Technical indicators show bullish momentum with the current price near resistance at $249, while RSI suggests potential oversold conditions at lower timeframes.

AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 price target offering 12.6% upside. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s and regulatory risks require monitoring. The company's dividend growth streak and robust pipeline support long-term value, but investors should weigh execution risks against current valuation multiples.

Home Depot (HD) trades at $354.48, down 0.32% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $368.75. The stock shows strong profitability with a net margin of 8.41% and ROE of 128.38%, though recent earnings have been mixed with a Q3 2025 miss but Q4 2025 and Q1 2026 beats. Revenue grew to $159.51 billion in 2025, while cash flow from operations remains robust at $19.81 billion, supporting a recent dividend of $2.33 per share.

The outlook is supported by analyst optimism (59% buy ratings) and Pro business growth, but risks include weakening big-ticket demand, margin pressures from investments, and sensitivity to housing market trends. The stock's valuation at a P/E of 24.91 may limit near-term upside if earnings growth slows.